Yesterday, a Director at Colfax (CFX), Rajiv Vinnakota, sold shares of CFX for $49.39K.
See today’s analyst top recommended stocks >>
Based on Colfax’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $816 million and quarterly net profit of $4.48 million. In comparison, last year the company earned revenue of $684 million and had a GAAP net loss of $52.02 million. The company has a one-year high of $39.30 and a one-year low of $12.23. Currently, Colfax has an average volume of 871.04K.
Based on 9 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $31.11, reflecting a -1.9% downside.
The insider sentiment on Colfax has been neutral according to 44 insider trades in the past three months. This sentiment is slightly lower than the average sentiment of company insiders in this sector.
Rajiv Vinnakota’s trades have generated a 8.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Colfax Corp. operates as a diversified technology company that provides orthopedic care and fabrication technology products and services to customers. The firm operates its business through the following segments: Medical Technology; and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices with a broad range of products used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures, and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Annapolis Junction, MD.
